Relation between circulating soluble Fas ligand and subsequent ventricular remodelling following myocardial infarction

Heart

Volumn 89, Issue 3, 2003, Pages 339-341

  Soeki, Takeshi ^a,b   Tamura, Y ^a   Shinohara, H ^a   Sakabe, K ^a   Onose, Y ^a   Fukuda, N ^a  

^a National Hospital Organization   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; MEMBRANE PROTEIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037372441     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.3.339     Document Type: Article

References (5)

1. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
2. Ohtsuka T, Hamada M, Sasaki O, et al. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coronary Artery Disease 1999;10:221-5.
3. Shimizu M, Fukuo K, Nagata S, et al. Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J Am Coll Cardiol 2002;39:585-90.
4. Cheng W, Kajstura J, Nitahara JA, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 1996;226:316-27.
5. Misao J, Hayakawa Y, Ohno M, et al. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996;94:1506-12.